Skip to main content

Zhengye Biotechnology Holding L (ZYBT) Stock

Zhengye Biotechnology Holding L Stock Details, Movements and Public Alerts

Stock Details

Zhengye Biotechnology Holding L (ZYBT), a prominent company in the healthcare sector within the drug manufacturers - specialty & generic industry, is based in China and primarily trades on the NCM.Currently, the stock is trading at $1.32. Over the past 52 weeks, it has ranged between $0.62 and $8.01. This places the current price at 16.5% of its 52-week high and 114.3% above its 52-week low. Recent trading volume was recorded at 122,913. The 14-day Relative Strength Index (RSI) stands at 43.09, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $1.49 by 11.41%. Similarly, it is above its 200-day moving average of $1.16 by 13.79%. The MACD histogram is -0.01, indicating bearish momentum0.

52-Week Range

$8.01 - $0.62

-83.52% from high · +114.29% from low

Avg Daily Volume

1,758,980

20-day average

100-day avg: 3,484,838

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Price to Book

1.65

EV/EBITDA

-3.17

EPS (TTM)

-$0.20

Price to Sales

0.53

Q:How is ZYBT valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is ZYBT's risk profile compared to the market?
Risk profile data is not available for this stock.

Performance & Growth

Profit Margin

-59.97%

Operating Margin

-77.04%

EBITDA

$-44,623,000

Return on Equity

-25.17%

Return on Assets

-9.48%

Revenue Growth (YoY)

-40.90%

Q:How profitable and efficient is ZYBT's business model?
Zhengye Biotechnology Holding L achieves a profit margin of -59.97%, meaning it retains $-59.97 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of -77.04% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -25.17% and ROA at -9.48%, the company achieves moderate returns on invested capital.
Q:What are ZYBT's recent growth trends?
Zhengye Biotechnology Holding L's revenue declined by 40.90% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. These growth metrics should be evaluated against Drug Manufacturers - Specialty & Generic industry averages for proper context.

Company Size & Market

Market Cap

$61.6M

Revenue (TTM)

$116.36M

Revenue/Share (TTM)

$2.46

Shares Outstanding

47.39M

Book Value/Share

$0.79

Asset Type

EQUITY

Q:What is ZYBT's market capitalization and position?
Zhengye Biotechnology Holding L has a market capitalization of $61.6M, classifying it as a small-cap stock (under $2B). Small-caps offer significant growth potential but come with higher volatility and risk. They can be more sensitive to economic conditions but may provide outsized returns if successful. With 47.39M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Drug Manufacturers - Specialty & Generic industry, it competes with other firms in this sector.
Q:How does ZYBT's price compare to its book value?
Zhengye Biotechnology Holding L's book value per share is $0.79, while the current stock price is $1.32, resulting in a price-to-book (P/B) ratio of 1.67. This reasonable premium to book value suggests the market values the company's earnings power and intangible assets appropriately. Most profitable companies trade between 1-3x book value. As EQUITY, this represents a specific type of security.

Fundamentals last updated: Oct 31, 2026, 02:21 AM

Technical Indicators

RSI (14-day)

43.09

Neutral

50-Day Moving Average

$1.49

-11.41% below MA-50

200-Day Moving Average

$1.16

13.79% above MA-200

MACD Line

N/A

MACD Signal

N/A

MACD Histogram

-0.01

Bearish

Q:What does ZYBT's RSI value tell investors?
The RSI (Relative Strength Index) for ZYBT is currently 43.09, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret ZYBT's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.00 below the signal line at 0.00, with histogram at -0.01. This bearish crossover indicates downward pressure. The narrow histogram suggests a potential trend change ahead. The 50-day MA ($1.49) is above the 200-day MA ($1.16), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Oct 31, 2026, 01:12 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for ZYBT and get notified when the price changes.

Stay Ahead of the Market with Zhengye Biotechnology Holding L Alerts

Set up price alerts for Zhengye Biotechnology Holding L and get notified instantly when the price hits your target. Never miss an important price movement again.